Retrospective Analysis of the Results of High-dose Chemotherapy with the Support of Autologous Blood Stem Cells in Patients with Multiple Myeloma. The Experience of a Single Centre

Abstrakt

We analyzed a group of 190 patients who underwent ASCT at our clinic for multiple myeloma as primary therapy in years 1995–2008. The assessment of the best therapeutic effect of ASCT showed the total rates of patients with complete remission – 22%, very good partial remission (VGPR)– 8%, partial remission – 63%, stabilized disease – 6% and progression – 1%.

The transplant related mortality (TRM) was 4.1%. With the median follow-up of surviving patients 2.6 years, the median progression-free survival (PFS) and overall survival (OS) were 21 and 54 months, respectively; the likelihood of a 7-year OS was 28%.

Comparing tandem versus single transplants, there was a significant increase in the median PFS, however, there was no difference in OS. The IVE mobilization regimen was found to be more efficacious than high dose cyclophosphamide.